Kalaris Therapeutics Inc (KLRS) Total Return Calculator with Dividends Reinvested

Kalaris Therapeutics Inc

Popular:

The total return for Kalaris Therapeutics Inc (KLRS) stock is +56.88% over the past 12 months. So far it's down 47.83% this year. The 5-year total return is -52.52%, meaning $10,000 invested in KLRS stock 5 years ago would be worth $4,748 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in KLRS 1 year ago, it would be worth $16,402 today — you'd have gained $6,402.

With Dividends Reinvested$16,402+64.02%

Price Only (No DRIP)$16,402+64.02%

Period2025-06-13 → 2026-06-12

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in KLRS

1Y$15,688+$5,688 (+56.9%)56.9% CAGR

3Y$4,748-$5,252 (-52.5%)-22.0% CAGR

5Y$4,748-$5,252 (-52.5%)-13.8% CAGR

10Y$4,748-$5,252 (-52.5%)-7.2% CAGR

15Y$4,748-$5,252 (-52.5%)-4.8% CAGR

20Y$4,748-$5,252 (-52.5%)-3.7% CAGR

30Y$4,748-$5,252 (-52.5%)-2.5% CAGR

Kalaris Therapeutics Inc did not pay dividends during this period. Total return = price return.

Loading KLRS total return...

As of 2026-06-13

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-47.83%	—	-47.83%	—	$5,217
1Y	+56.88%	56.88%	+56.88%	—	$15,688
3Y	-52.52%	-21.99%	-52.52%	—	$4,748
5Y	-52.52%	-13.84%	-52.52%	—	$4,748
10Y	-52.52%	-7.18%	-52.52%	—	$4,748
15Y	-52.52%	-4.84%	-52.52%	—	$4,748
20Y	-52.52%	-3.66%	-52.52%	—	$4,748
30Y	-52.52%	-2.45%	-52.52%	—	$4,748

Risk & Highlights

Best Year-7.46%2025

Max Drawdown-62.80%2026-02-19 → 2026-06-09

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	+26.02%	+26.02%	—	+0.41%	+25.6pp
2025	-7.46%	-7.46%	—	+16.64%	-24.1pp

KLRS outperformed the S&P 500 by 34.03pp over the past year (+56.88% vs +22.86%).

Loading summary...

KLRS Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
KLRSKalaris Therapeutics Inc	$81M	-9.6%	-47.8%	+56.9%	—	-52.5%	-52.5%	-52.5%
REPLReplimune Group, Inc.	$733M	+117.1%	-0.2%	-10.2%	—	-62.1%	-74.4%	-41.4%
ADMAADMA Biologics, Inc.	$1.9B	-2.4%	-54.1%	-62.0%	—	+112.1%	+346.2%	+15.3%
TGTXTG Therapeutics, Inc.	$7.6B	+16.4%	+69.1%	+32.5%	—	+89.0%	+29.3%	+605.4%
KYMRKymera Therapeutics, Inc.	$7.0B	+3.2%	+18.5%	+82.3%	—	+242.9%	+70.4%	+159.2%
IMVTImmunovant, Inc.	$6.9B	+17.3%	+29.8%	+110.9%	—	+55.0%	+213.0%	+237.9%
ARQTArcutis Biotherapeutics, Inc.	$3.0B	+17.8%	-15.9%	+80.6%	—	+138.8%	-16.2%	+11.8%
RCUSArcus Biosciences, Inc.	$2.4B	-4.4%	+2.2%	+154.5%	—	+18.3%	-3.1%	+40.0%
FATEFate Therapeutics, Inc.	$240M	-8.4%	+108.1%	+47.1%	—	-61.9%	-97.7%	+15.7%
AGENAgenus Inc.	$137M	-4.1%	+2.2%	-31.5%	—	-91.8%	-96.8%	-95.9%
NKTRNektar Therapeutics	$1.2B	-24.3%	+36.8%	+577.9%	—	+594.5%	-77.6%	-73.6%

Compare:KLRS vs REPL KLRS vs ADMA KLRS vs TGTX KLRS vs REPL vs ADMA

About KLRS Dividend Returns

Kalaris Therapeutics Inc (KLRS) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of KLRS over the past year?

Kalaris Therapeutics Inc (KLRS) delivered a return of 56.88% over the past year. Since KLRS does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in KLRS be worth today?

A $10,000 investment in Kalaris Therapeutics Inc one year ago would be worth $15,688 today, representing a gain of $5,688.

Q3Does KLRS pay dividends?

Kalaris Therapeutics Inc (KLRS) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For KLRS, the total return equals the price-only return.

Q4Did KLRS beat the S&P 500?

Yes, Kalaris Therapeutics Inc (KLRS) outperformed the S&P 500 by 34.03 percentage points over the past year. KLRS delivered a total return of 56.88%, compared to the S&P 500's 22.86%. This 34.03pp alpha means investors in KLRS earned more than a passive S&P 500 index fund.

Q5What is KLRS's worst drawdown?

Kalaris Therapeutics Inc (KLRS) experienced a maximum drawdown of -62.80% over the past year, declining from its peak on 2026-02-19 to its trough on 2026-06-09. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is KLRS's long-term total return over 10, 20, or 30 years?

Here are Kalaris Therapeutics Inc (KLRS)'s long-term returns with dividends reinvested. Over 10 years, the total return is -52.5% (-7.2% CAGR) — $10,000 would have grown to $4,748. Over 20 years: -52.5% total return (-3.7% CAGR) — $10,000 → $4,748. Over 30 years: -52.5% total return (-2.5% CAGR) — $10,000 → $4,748. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

How much would $100/month in KLRS be worth today?

Dollar cost averaging calculator · DCA vs lump sum · see how regular investing compounds

Run the Numbers →